Reardon Andrew bought LGND
June 30, 2025 · Form 4 insider transaction
Reardon Andrew bought 233 shares of Ligand Pharmaceuticals Incorporated at $91.08 per share, a transaction worth $21.2K. The trade was recorded as j and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
233
Price
$91.08
Total value
$21.2K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeJ: J
Transaction dateJune 30, 2025
Filing dateJuly 2, 2025
Shares owned after32,136
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).